ETON
Chart
Ratings & dials
1m · 5m · 15m · 1h · 4h · 1DAnalyst & Morningstar ratings
Consensus · Targets · MorningstarThird-party ratings, not SURVYR.'s views.
Health check
See the tests
- ✗Positive net income
- ✓Positive operating cash flow
- ✓Return on assets improved
- ✓Cash flow above net income
- ✓Long-term debt / assets fell
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.
Key stats & company
What they do
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus.
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.90 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $2.55 vs trailing $0.40 (+537% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 5/9 · last two fiscal years
Altman Z-score 12.8 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $80.0M | $-4.6M | $10.2M |
| 2024 | $39.0M | $-3.8M | $943.0K |
| 2023 | $31.6M | $-936.0K | $6.8M |
| 2022 | $21.3M | $-9.0M | $4.8M |
| 2021 | $21.8M | $-2.0M | $-4.7M |
| 2020 | $39.0K | $-28.0M | $-22.4M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +55.5%.
For information only · Important disclosures
Grades vs sector
No sector grades for ETON yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Held by 1 of 7 live models: New Highs Growth.
Earnings & events
ETON earningsNext report in 16 daysIn line = within 1% of the estimate.
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $37.6M | +98.6% |
| 2026-03-31 | $24.3M | – |
| 2025-12-31 | $21.3M | – |
| 2025-09-30 | $22.5M | – |
| 2025-06-30 | $18.9M | – |
News & catalysts
More newsResearch
Rating changes
Third-party analyst actions, not SURVYR.'s views. All rating changes
Insider trades
$229.4K
$7.9K
$811.9K
$2.1M
$1.6M
$456.1K
$2.2M
$2.8M
$562.5K
–
–
–
Stats refreshed 2026-10-25 14:25:42 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Get the market emails
Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdaysIndexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.
Check your inbox to confirm
We sent a link to . Tap it to start your emails. Nothing is sent until you confirm.
Not there in a minute? Check spam, or .
Dev mode No email provider here, so the confirm link is shown: Open confirm link
Free to use. No card, no ads, no auto-renew.
Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Coteau 0.9 · Oct 21, 2026